BPC-157
Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases
NH SB252 further expanded telehealth prescribing flexibility, and the practical result is that most NH residents in 2026 can complete a full GLP-1 intake medical history, BMI verification, lab review where applicable, and prescription without ever driving to Manchester, Nashua, or Concord
These changes apply across settings, including office/outpatient visits, inpatient or observation care, consultations, emergency department visits, nursing facility services, home/residence services and prolonged services
The company was proposing AVT04 as a biosimilar to J&Js Stelara (ustekinumab), which binds to binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses